411 related articles for article (PubMed ID: 2170624)
1. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
2. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
[TBL] [Abstract][Full Text] [Related]
4. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
7. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Cailleau C; Maffrand JP
J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
9. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
10. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
Floch A; Tahraoui L; Sedivy P; Cavero I
J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of platelet activating factor receptor binding and stimulated phosphoinositide-specific phospholipase C in rabbit platelets.
Morrison WJ; Shukla SD
J Pharmacol Exp Ther; 1989 Sep; 250(3):831-5. PubMed ID: 2550620
[TBL] [Abstract][Full Text] [Related]
12. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
13. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
14. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
16. PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover.
Catalán RE; Martínez AM; Aragonés MD; Lombardía M; Garde E
Eur J Pharmacol; 1995 Aug; 290(3):183-8. PubMed ID: 7589212
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
18. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
